Atrion (NASDAQ:ATRI) Trading Up 5.6%

Atrion Co. (NASDAQ:ATRI) shares shot up 5.6% during trading on Friday . The company traded as high as $407.29 and last traded at $407.29. 27,813 shares traded hands during trading, an increase of 63% from the average session volume of 17,037 shares. The stock had previously closed at $385.70.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Atrion from a “sell” rating to a “hold” rating in a research note on Friday, March 1st.

Atrion Price Performance

The firm has a 50 day simple moving average of $400.65 and a 200-day simple moving average of $365.24. The stock has a market capitalization of $716.83 million, a price-to-earnings ratio of 34.97 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last released its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The firm had revenue of $43.58 million during the quarter.

Atrion Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were given a $2.20 dividend. This represents a $8.80 annualized dividend and a yield of 2.16%. The ex-dividend date was Thursday, March 14th. Atrion’s dividend payout ratio (DPR) is presently 79.78%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Copeland Capital Management LLC raised its position in shares of Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 31 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in Atrion in the fourth quarter valued at about $36,000. FMR LLC lifted its stake in Atrion by 38.0% in the first quarter. FMR LLC now owns 69 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 19 shares during the period. Qube Research & Technologies Ltd bought a new position in Atrion during the third quarter worth about $60,000. Finally, Advisor Group Holdings Inc. acquired a new position in shares of Atrion during the 4th quarter worth about $65,000. 66.19% of the stock is currently owned by institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.